Ian Davis

Continuous Bladder Irrigation after Transurethral Resection of Non-Muscle Invasive Bladder Cancer for Prevention of Tumour Recurrence - A Systematic Review

M Li, J Toniolo, R Nandurkar, N Papa, N Lawrentschuk, ID Davis, S Sengupta

Conference Proceedings  |  2020  |  Urologic Oncology Seminars and Original Investigations

Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial

Andrew Kneebone, Carol Fraser-Browne, Gillian M Duchesne, Richard Fisher, Mark Frydenberg, Alan Herschtal, Scott G Williams, Chris Brown, Warick Delprado, Annette Haworth, David J Joseph, Jarad M Martin, John HL Matthews, Jeremy L Millar, Mark Sidhom, Nigel Spry, Colin I Tang, Sandra Turner, Kirsty L Wiltshire, Henry H Woo, et al.

Journal article  |  2020  |  The Lancet Oncology

Background: Adjuvant radiotherapy has been shown to halve the risk of biochemical progression for patients with high-risk disease ..

Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Frede Donskov, Wanling Xie, Anders Overby, J Connor Wells, Anna P Fraccon, Cosimo S Sacco, Camillo Porta, Igor Stukalin, Jae-Lyun Lee, Konstantinos Koutsoukos, Takeshi Yuasa, Ian D Davis, Carmel Pezaro, Ravindran Kanesvaran, Georg A Bjarnason, Hao-Wen Sim, Nityam Rathi, Christian K Kollmannsberger, Christina M Canil, Toni K Choueiri, et al.

Journal article  |  2020  |  European Urology Oncology

Nursing Implications of Recent Changes in Management Practices for Metastatic Prostate Cancer.

Caitlin Bennett, Ian D Davis, Anis A Hamid

Journal article  |  2020  |  Seminars in Oncology Nursing

OBJECTIVE: Prostate cancer is one of the most common male cancers in the world and accounts for substantial morbidity, mortality, ..

Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer.

Heidi Fettke, Edmond M Kwan, Patricia Bukczynska, Nicole Ng, Tu Nguyen-Dumont, Melissa C Southey, Ian D Davis, Andrew Mant, Phillip Parente, Carmel Pezaro, Christine Hauser, Arun A Azad

Journal article  |  2020  |  European Urology Focus

Total plasma cell-free DNA (cfDNA) levels were recently shown to be prognostic in two large phase III trials of taxane chemotherap..

Compliance with follow-up for patients with stage 1 testicular germ cell tumour

King Tung Cheung, Anthony Dat, Peter Wong, Caroline Dowling, Ian D Davis, Shomik Sengupta

Journal article  |  2020  |  ANZ Journal of Surgery

BACKGROUND: This study aimed to evaluate the compliance and loss-to-follow-up (LTFU) rate in patients with stage 1 testicular germ..

TheraP: A randomised phase II trial of Lu-177-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).

Michael S Hofman, Louise Emmett, Shahneen Kaur Sandhu, Amir Iravani, Anthony M Joshua, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Siobhan Ng, Roslyn J Francis, Craig Gedye, Natalie K Rutherford, Alison Yan Zhang, Margaret Mary McJannett, Martin R Stockler, John A Violet, Scott Williams, Andrew James Martin, Ian D Davis

Conference Proceedings  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

A Simple Clinical Tool for Stratifying Risk of Clinically Significant CKD after Nephrectomy: Development and Multinational Validation

Robert J Ellis, Sharon J Del Vecchio, Kevin MJ Gallagher, Danielle N Aliano, Neil Barber, Damien M Bolton, Etienne TS Chew, Jeff S Coombes, Michael D Coory, Ian D Davis, James F Donaldson, Ross S Francis, Graham G Giles, Glenda C Gobe, Carmel M Hawley, David W Johnson, Alexander Laird, Steve Leung, Manar Malki, David JT Marco, et al.

Journal article  |  2020  |  Journal of the American Society of Nephrology

BACKGROUND: Clinically significant CKD following surgery for kidney cancer is associated with increased morbidity and mortality, b..

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

Silke Gillessena, Gerhardt Attard, Tomasz M Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Rob G Bristow, Kim N Chi, Noel Clarke, Ian D Davis, Johann de Bono, Charles G Drake, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Christopher P Evans, Stefano Fanti, Felix Y Feng, Karim Fizazi, et al.

Journal article  |  2020  |  European Urology

BACKGROUND: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes,..

DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate-A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer

Tamim Niazi, Scott Williams, Ian D Davis, Martin R Stockler, Andrew James Martin, Wendy Hague, Karen Bracken, Margot Gorzeman, Felicia Roncolato, Sonia Yip, Lisa Horvath, Shomik Sengupta, Simon Hughes, Raymond S McDermott, James WF Catto, Neha Vapiwala, Wendy R Parulekar, Christopher Sweeney

Conference Proceedings  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY